Therapeutic Asset Ratings
5,108 results matching 1 filter
91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
FLUOROURACILUM
Esophageal Squamous Cell Carcinoma
AstraZeneca
P3
BB
(66)
FLUOROURACILUM
Gastric Adenocarcinoma
Boehringer Ingelheim
P3
BB
(66)
FLUOROURACILUM
HIV Infectious Disease
National Cancer Institute (NCI)
P3
BB
(66)
FLUOROURACILUM
Intestinal Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
BB
(66)
FLUOROURACILUM
Neuroendocrine Neoplasm
ITM Solucin GmbH
P3
BB
(66)
Fruquintinib
Non-Small Cell Lung Carcinoma
Immunitas Therapeutics
P3
BB
(66)
Ganaxolone
Tuberous Sclerosis
Marinus Pharmaceuticals
P3
BB
(66)
Gilteritinib
Myelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland
P3
BB
(66)
Girentuximab
Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
P3
BB
(66)
Gls-010
Classic Hodgkin Lymphoma
Guangzhou Gloria Biosciences Co., Ltd.
P3
BB
(66)
Goserelin
Castration-Resistant Prostate Carcinoma
Bayer
P3
BB
(66)
Goserelin
Estrogen-Receptor Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
P3
BB
(66)
Goserelin
Female Breast Carcinoma
Ahon Pharmaceutical Co., Ltd.
P3
BB
(66)
Gozetotide
Prostate Cancer
University of Texas Southwestern Medical Center
P3
BB
(66)
hrg2010
Parkinson Disease
Jiangsu HengRui Medicine Co., Ltd.
P3
BB
(66)
hsk44459
Idiopathic Pulmonary Fibrosis
Haisco Pharmaceutical Group Co., Ltd.
P3
BB
(66)
HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) BASED LENTIVIRAL VECTOR (LVV) PSEUDOTYPED WITH THE VESICULAR STOMATITIS VIRUS GLYCOPROTEIN G (VSV-G) ENVELOPE PROTEIN, AND ENCODING THE C11D5.3 ANTI-TNF RECEPTOR SUPERFAMILY MEMBER 17 (TNFRSF17, BCMA) SINGLE CHAIN VARIABLE FRAGMENT (SCFV) CD8/4-1BB/CD3ZETA CHIMERIC ANTIGEN RECEPTOR (CAR) UNDER THE TRANSCRIPTIONAL CONTROL OF THE MYELOPROLIFERATIVE SARCOMA VIRUS ENHANCER, NEGATIVE CONTROL REGION DELETED, DL587REV PRIMER-BINDING SITE SUBSTITUTED (MND) PROMOTE
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P3
BB
(66)
HUMAN FAECAL MATTER
Cirrhosis Of Liver
VA Office of Research and Development
P3
BB
(66)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa
Non-Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
P3
BB
(66)
Humax-Cd20
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PETHEMA Foundation
P3
BB
(66)
Hydrocortisone
B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
P3
BB
(66)
Hydrocortisone
Childhood Acute Myeloid Leukemia
Children's Oncology Group
P3
BB
(66)
Hydrocortisone
T-Cell Childhood Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
P3
BB
(66)
Hydronidone
Chronic Hepatitis B Virus Infection
Beijing Continent Pharmaceutical Co, Ltd.
P3
BB
(66)
Hydroxyurea
Hemoglobinopathy
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
P3
BB
(66)
Showing 1176 to 1200 of 5,108 assets
Previous
Page 48 of 205
Next